Abstract

Simple SummaryLong non-coding RNAs (lncRNAs) can be detected in a liquid biopsy. We herein discussed the origin, methods of detection, measurement and potential functions of lncRNAs in blood. Furthermore, we used a systematic literature search to identify thirteen circulating lncRNAs whose expression was associated with bone tumor and we examined their impacts on clinical decision-making in the management of osteosarcoma.Circulating cell-free nucleic acids recently became attractive targets to develop non-invasive diagnostic tools for cancer detection. Along with DNA and mRNAs, transcripts lacking coding potential (non-coding RNAs, ncRNAs) directly involved in the process of tumor pathogenesis have been recently detected in liquid biopsies. Interestingly, circulating ncRNAs exhibit specific expression patterns associated with cancer and suggest their role as novel biomarkers. However, the potential of circulating long ncRNAs (c-lncRNAs) to be markers in osteosarcoma (OS) is still elusive. In this study we performed a systematic review to identify thirteen c-lncRNAs whose altered expression in blood associate with OS. We herein discuss the potential impact that these c-lncRNAs may have on clinical decision-making in the management of OS. Overall, we aimed to provide novel insights that can contribute to the development of future precision medicine in oncology.

Highlights

  • Osteosarcoma (OS) is a highly aggressive malignant bone tumor, frequently occurring in children and adolescents with an annual incidence of over three per million worldwide [1,2,3]

  • We found that the majority of the circulating long non-coding RNA (lncRNA) that have been studied for their potential as biomarkers for OS, so far, are very large (above 2000 nucleotides) with a complex transcriptional organization that produces several different splicing variants (SVs)

  • The role of lncRNAs in OS tumor development has only recently been investigated, yet several studies have shown that the deregulation of a number of lncRNAs influence the occurrence and progression of osteosarcoma, as reviewed in [153]

Read more

Summary

Introduction

Osteosarcoma (OS) is a highly aggressive malignant bone tumor, frequently occurring in children and adolescents with an annual incidence of over three per million worldwide [1,2,3]. OS represents different pathological entities based on clinical, radiological, and histopathological features. Based on histopathological features, osteosarcoma can be classified into distinct subtypes with the osteoblastic, chondroblastic, and fibroblastic OS, respectively, being the most common [4]. Approximately 20% of patients showed clinical metastasis at presentation, with a 5-year survival rate less than 30% [7]. For this reason, OS strongly demands reliable, non-invasive, and clinically useful biomarkers

Objectives
Methods
Findings
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call